Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.65 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.60 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Alcohol SCHEMBL6851692 | 0.96 | KDM4E (0.61) | KDM4EHIF1AMAPTSLC22A6SLC22A8 | |
| Hippuric Acid SCHEMBL7486 | 0.88 | GAA (0.68) | KDM4EHIF1AMAPTSLC22A6SLC22A8 | |
| SCHEMBL22030672 | 0.88 | GAA (0.68) | KDM4EHIF1AMAPTSLC22A6SLC22A8 | |
| Hippuric Acid SCHEMBL428479 | 0.88 | GAA (0.68) | KDM4EHIF1AMAPTSLC22A6SLC22A8 | |
| SCHEMBL11107537 | 0.88 | KDM4E (0.80) | KDM4EHIF1AMAPTSLC22A6SLC22A8 | |
| Hippuric Acid SCHEMBL15416338 | 0.86 | MAPT (0.66) | KDM4EHIF1AMAPTSLC22A6SLC22A8 | |
| Hippuric Acid SCHEMBL11709120 | 0.86 | MAPT (0.66) | KDM4EHIF1AMAPTSLC22A6SLC22A8 | |
| Hippuric Acid SCHEMBL21569381 | 0.86 | MAPT (0.66) | KDM4EHIF1AMAPTSLC22A6SLC22A8 | |
| Hippuric Acid SCHEMBL657588 | 0.86 | KDM4E (0.66) | KDM4EHIF1AMAPTSLC22A6SLC22A8 | |
| Hippuric Acid SCHEMBL3448563 | 0.86 | MAPT (0.66) | KDM4EHIF1AMAPTSLC22A6SLC22A8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217708-B2 | Cardiovascular disorders | ASTRAZENECA AB (SE) | 2007-05-15 | — | — | US | claimed |
| EP-1389213-B1 | 3,7-DIAZABICYCLO 3.3.1| FORMULATIONS AS ANTIARHYTHMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2006-04-12 | — | — | EP | claimed |
| EP-1550663-A1 | New crystalline forms of antiarrhythmic compounds | Astra Zeneca AB (SE) | 2005-07-06 | — | — | EP | claimed |
| US-20040143000-A1 | 3,7-diazabicyclo [3.3.1] formulations as antiarhythmic compounds | ASTRAZENECA AB (SE) | 2004-07-22 | — | — | US | claimed |
| EP-1389213-A1 | 3,7-DIAZABICYCLO 3.3.1] FORMULATIONS AS ANTIARHYTHMIC COMPOUNDS | AstraZeneca AB (SE) | 2004-02-18 | — | — | EP | claimed |
| WO-2002083688-A1 | 3,7-DIAZABICYCLO [3.3.1] FORMULATIONS AS ANTIARHYTHMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | claimed |
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| WO-2023183405-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023183405-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2019154306-A1 | SACCHARIDE DERIVATIVES FOR IMMUNE CELL SURFACE MODIFICATION AND USE THEREOF | 厦门诺康得生物科技有限公司 | 2019-08-15 | — | — | WO | disclosed |
| US-8129376-B2 | Piperidine derivatives as inhibitors of stearoyl-CoA desaturase | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-03-06 | — | — | US | disclosed |
| US-8129376-B2 | Piperidine derivatives as inhibitors of stearoyl-CoA desaturase | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-03-06 | — | — | US | disclosed |
| US-8129376-B2 | Piperidine derivatives as inhibitors of stearoyl-CoA desaturase | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-03-06 | — | — | US | disclosed |
| US-4738978-A | ANTICOAGULANT, ANTIALLERGENS | E. R. SQUIBB & SONS, INC. (US) | 1988-04-19 | — | — | US | disclosed |
| US-4735962-A | ANTICOAGULANTS, BRONCHODILATORS | E. R. SQUIBB & SONS, INC. (US) | 1988-04-05 | — | — | US | disclosed |
| US-4734424-A | ANTICOAGULANTS | E. R. SQUIBB & SONS, INC. (US) | 1988-03-29 | — | — | US | disclosed |
| US-4734426-A | CARDIOVASCULAR AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1988-03-29 | — | — | US | disclosed |
| US-4663336-A | ANTICOAGULANTS | E. R. SQUIBB & SONS, INC. (US) | 1987-05-05 | — | — | US | disclosed |
| US-4638012-A | 7-oxabicycloheptane α-substituted ketone prostaglandin analogs useful in the treatment of thrombotic disease | E. R. SQUIBB & SONS, INC. (US) | 1987-01-20 | — | — | US | disclosed |
| EP-0207684-A2 | 7-Oxabicycloheptane substituted diamide and its congener prostaglandin analogs | E.R. Squibb & Sons, Inc. (US) | 1987-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C5, C1S, C9 | KDM4E 4647/4885HIF1A 3524/4885MAPT 1464/4885 |
| US-20040143000-A1 | 3,7-diazabicyclo [3.3.1] formulations as antiarhythmic compounds | SCN3A, KCNH1, CACNA1G | KDM4E 743/4885HIF1A 3514/4885MAPT 3991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.